{"id":"NCT02822573","sponsor":"Wake Forest University Health Sciences","briefTitle":"Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil","officialTitle":"A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-30","primaryCompletion":"2022-07-29","completion":"2022-07-29","firstPosted":"2016-07-04","resultsPosted":"2023-09-13","lastUpdate":"2023-09-13"},"enrollment":276,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cognitive Dysfunction","Memory Impairment"],"interventions":[{"type":"DRUG","name":"Donepezil 5 mg","otherNames":["Aricept"]},{"type":"DRUG","name":"Placebo","otherNames":["Sugar Pill"]}],"arms":[{"label":"Donepezil","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is to compare the safety and effects of donepezil (Aricept) for patients reporting cognitive or memory issues after receiving chemotherapy for breast cancer. Patients will receive either donepezil or placebo for 24 weeks. The primary objective is to see if memory improves with the use of donepezil during the study.","primaryOutcome":{"measure":"Hopkins Verbal Learning Test-Revised (HVLT-R) - Total","timeFrame":"Baseline, Weeks 12, 24, 36","effectByArm":[{"arm":"Donepezil","deltaMin":24.4,"sd":null},{"arm":"Placebo","deltaMin":24.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.32"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":22},"locations":{"siteCount":278,"countries":["United States"]},"refs":{"pmids":["38709986"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":140},"commonTop":[]}}